T1	Condition 42 67	major depressive disorder
T2	Qualifier 85 90	DSM-V
T3	Procedure 142 237	Structured Clinical Interview for DSM-V Axis I Disorders, Research Version, Non-patient Edition
R1	Has_qualifier Arg1:T1 Arg2:T2	
R2	AND Arg1:T1 Arg2:T3	
T4	Condition 294 311	suicidal ideation
T5	Condition 294 302;316 325	suicidal behaviour
T6	Condition 337 346	self-harm
T7	Condition 354 368	harm to others
*	OR T5 T4 T6 T7
T8	Condition 384 399	substance abuse
T9	Condition 384 393;407 417	substance dependence
*	OR T8 T9
T10	Procedure 431 460	drug screen for illicit drugs
T11	Value 422 430	positive
R3	Has_value Arg1:T10 Arg2:T11	
T12	Condition 462 485	Substantial alcohol use
T13	Drug 502 538	Monoamine Oxidase Inhibitors (MAOIs)
T14	Drug 554 574	antibiotic linezolid
T15	Drug 583 595	thiazine dye
T16	Drug 596 621	methylthioninium chloride
R4	Subsumes Arg1:T15 Arg2:T16	
T17	Drug 623 637	methylene blue
R5	Subsumes Arg1:T16 Arg2:T17	
*	OR T14 T15
T18	Scope 554 638	antibiotic linezolid and the thiazine dye methylthioninium chloride (methylene blue)
R6	Subsumes Arg1:T13 Arg2:T18	
T19	Drug 655 675	serotonin-precursors
T20	Drug 685 697	L-tryptophan
T21	Drug 699 709	oxitriptan
*	OR T21 T20
T22	Scope 685 709	L-tryptophan, oxitriptan
R7	Subsumes Arg1:T19 Arg2:T22	
T23	Drug 727 745	serotonergic drugs
T24	Drug 747 755	triptans
T25	Drug 765 789	tricyclic antidepressant
T26	Drug 792 799	lithium
T27	Drug 801 809	tramadol
T28	Drug 811 826	St. John's Wort
*	OR T28 T27 T26 T25 T24
T29	Scope 747 826	triptans, certain tricyclic antidepressants, lithium, tramadol, St. John's Wort
R8	Subsumes Arg1:T23 Arg2:T29	
T30	Drug 848 854	NSAIDS
T31	Drug 856 859	ASA
T32	Drug 871 885	anticoagulants
T33	Qualifier 865 870	other
R9	Has_qualifier Arg1:T32 Arg2:T33	
*	OR T31 T32 T30
T34	Drug 903 915	Thioridazine
T35	Temporal 829 840	Concomitant
T36	Scope 848 885	NSAIDS, ASA, and other anticoagulants
R10	Has_temporal Arg1:T36 Arg2:T35	
T37	Drug 932 949	CYP1A2 Inhibitors
T38	Drug 966 974	Triptans
T39	Drug 976 989	5HT1 Agonists
R11	Subsumes Arg1:T38 Arg2:T39	
T40	Measurement 992 1006	Blood pressure
T41	Value 1007 1026	greater than 140/90
T42	Measurement 1036 1046	pulse rate
T43	Value 1047 1066	greater than 90 bpm
R12	Has_value Arg1:T42 Arg2:T43	
R13	Has_value Arg1:T40 Arg2:T41	
T44	Temporal 1068 1074	Recent
T45	Observation 1075 1082	history
T46	Condition 1086 1107	myocardial infarction
R14	Has_temporal Arg1:T45 Arg2:T44	
T47	Condition 1109 1133	cerebrovascular accident
T48	Condition 1135 1154	cardiac arrhythmias
T49	Condition 1159 1181	unstable heart disease
*	OR T49 T48 T47 T46
T50	Scope 1086 1181	myocardial infarction, cerebrovascular accident, cardiac arrhythmias, or unstable heart disease
R15	Has_temporal Arg1:T50 Arg2:T45	
T51	Condition 1208 1224	physical illness
T52	Condition 1225 1241	contraindicating
T53	Drug 1253 1268	levomilnacipran
T54	Drug 1273 1283	duloxetine
*	OR T53 T54
T55	Procedure 1297 1310	physical exam
T56	Procedure 1321 1331	laboratory
T57	Temporal 1346 1380	during the first week of the study
*	OR T55 T56
T58	Scope 1297 1331	physical exam or in the laboratory
T59	Scope 1253 1283	levomilnacipran and duloxetine
R16	AND Arg1:T51 Arg2:T52	
R17	Has_scope Arg1:T52 Arg2:T59	
R18	Has_scope Arg1:T51 Arg2:T58	
R19	Has_temporal Arg1:T58 Arg2:T57	
T60	Drug 1397 1407	medication
T61	Drug 1437 1453	anticholinergics
T62	Temporal 1382 1389	Current
R20	Has_temporal Arg1:T60 Arg2:T62	
T63	Condition 1417 1431	affect voiding
R21	Subsumes Arg1:T60 Arg2:T61	
R22	AND Arg1:T60 Arg2:T63	
T64	Condition 1467 1496	obstructive urinary disorders
T65	Condition 1501 1508	dysuria
T66	Condition 1510 1531	prostatic hypertrophy
T67	Condition 1533 1544	prostatitis
T68	Condition 1556 1597	lower urinary tract obstructive disorders
T69	Qualifier 1550 1555	other
R23	Has_qualifier Arg1:T68 Arg2:T69	
*	OR T67 T68 T66 T65 T64
T70	Observation 1456 1463	History
T71	Scope 1467 1597	obstructive urinary disorders and dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders
R24	Has_temporal Arg1:T71 Arg2:T70	
T72	Condition 1611 1635	Stevens-Johnson Syndrome
T73	Condition 1640 1659	Erythema multiforme
*	OR T73 T72
T74	Condition 1662 1677	Diabetes Type I
T75	Condition 1662 1675;1682 1684	Diabetes Type II
*	OR T75 T74
T76	Condition 1686 1706	Fructose intolerance
T77	Condition 1708 1739	glucose-galactose malabsorption
T78	Condition 1743 1775	sucrose-isomaltase insufficiency
*	OR T78 T77 T76
T79	Condition 1778 1796	Hepatic Impairment
T80	Condition 1811 1832	narrow-angle glaucoma
T81	Qualifier 1798 1810	Uncontrolled
R25	Has_qualifier Arg1:T80 Arg2:T81	
T82	Condition 1841 1857	renal impairment
T83	Qualifier 1834 1840	Severe
R26	Has_qualifier Arg1:T82 Arg2:T83	
T84	Condition 1870 1886	seizure disorder
T85	Observation 1859 1866	History
R27	Has_temporal Arg1:T84 Arg2:T85	
T86	Condition 1888 1921	Anatomically narrow ocular angles
T87	Condition 1924 1936	Osteoporosis
T88	Mood 1940 1950	major risk
T89	Condition 1955 1969	bone fractures
R28	Has_mood Arg1:T89 Arg2:T88	
*	OR T87 T89
